We unexpectedly noted that the higher degree of phenotypic heterogeneity revealed by mass spectrometry imaging in resected tumor tissue was associated with a favorable outcome in patients with locally advanced HER2-positive breast cancer treated with trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.